Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

Official title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes: Victorion - RIDES

Overview

The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.

Detailed description

This is a multicenter, prospective, randomized, double-blind, placebo-controlled, two arms, parallel groups clinical trial in participants experiencing an ACS (STEMI or NSTEMI) of recent onset. The study drug treatment (inclisiran/placebo) will be initiated at randomization (Day 1) and before discharge.

The study consists of:

1. Screening visit within 7 days (≤ 7 days) from hospital admission. Screening visit might happen at hospital admission day or any time after hospital admission and before randomization (Day 1). 2. Randomization/Baseline visit (Day 1) within 7 days (≤ 7 days) from hospital admission and before or at day of discharge.

The discharge can happen any time after randomization and first study drug administration (Day 1). 3. Double-blinded treatment period (150 days). 4. Scheduled safety calls in between visits during the double-blind treatment period (they do not replace on-site visits) 5. Safety Follow-up call (30 days after EOS visit)

Screening and randomization visits must happen during the in-hospital phase, within 7 days (≤ 7 days), and before discharge. The Screening period, of no more than 6 days after the date of hospital admission, will be used to determine if patients qualify to enter the double-blind treatment phase of the study. Screening and Randomization/Day 1 visits cannot occur on the same day. The overall study duration is 150 days.

Interventions

• Drug Placebo
  The participants will receive placebo subcutaneous at randomization (Day 1, Baseline visit) and Day 90
• Drug Inclisiran
  The participants will receive Inclisiran sodium 300 mg subcutaneous at randomization (Day 1, Baseline visit) and Day 90

Primary outcome measures

• Percent change in LDL-C [Time frame: From baseline to Day 150]

Secondary outcome measures (10)

• Participants achieving LDL-C <70 mg/dL (yes, no) [Time frame: At Day 150]
• Participants achieving LDL-C <55 mg/dL (yes, no) [Time frame: At Day 150]
• Participants achieving LDL-C <100 mg/dL (yes, no) (among the subset of participants with LDL-C ≥100 mg/dL at baseline) [Time frame: At Day 150]
• Participants achieving ≥50% reduction from baseline in LDL-C (yes, no) [Time frame: At Day 150]
• Percent change from baseline to mean LDL-C over the double-blind treatment period (averaged over all post-baseline visits) [Time frame: From baseline to Day 30, Day 90 and Day 150]
• Absolute change from baseline to mean LDL-C over the double-blind treatment period (averaged over all post-baseline visits) [Time frame: From baseline to Day 30, Day 90 and Day 150]
• Percent change in LDL-C [Time frame: From baseline to Day 30 and Day 90]
• Absolute change in LDL-C [Time frame: From baseline to Day 30, Day 90 and Day 150]
• Percent change and absolute change in PCSK9 [Time frame: From baseline to Day 30, Day 90 and Day 150]
• Percent change and absolute change from baseline in: apoB, VLDL, non-HDLC, HDL-C, total cholesterol and triglycerides [Time frame: At Day 150]

Eligibility criteria

Inclusion criteria

Participant eligible for inclusion in this study must meet all the following criteria:

At Screening:

• Signed informed consent must be obtained prior to participation in the study.
• Males and females, ≥18 years of age at the time of providing written informed consent.
• Ability to understand study's requirements and provide informed consent and comply with all required study procedures.
• Hospitalization for a ACS event (STEMI or NSTEMI).
• Receiving treatment for the qualifying ACS event, according to clinical judgement, by means of medical treatment alone or percutaneous coronary revascularization.
• Had a successful PCI (with or without stent) for the qualifying event if a PCI was required.
• LDL-C value at the Screening visit measured by the local lab of:

• LDL-C ≥70 mg/dL in participant previously treated with high-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day) or equivalent as per national guidelines and local regulation for at least 4 weeks before screening or
• LDL-C ≥100 mg/dL in participant previously treated with low/moderate-intensity statin for at least 4 weeks before screening or
• LDL-C ≥125 mg/dL in participant previously not treated with statins for at least 4 weeks before screening, or who never received statins (including statin intolerant participants).

At Randomization:

• The participant must have a Baseline fasting LDL-C ≥70 mg/dL (local lab assessment) to be eligible for randomization.
• Randomization within 7 days (≤ 7 days) following hospital admission for the qualifying ACS event and before/at discharge.

Exclusion criteria

Participant meeting any of the following criteria is not eligible for inclusion in this study.

Only for Japan: For exclusion criteria 6, investigator judgment should be documented in the source data document.

• Participant who is clinically unstable during hospitalization for the qualifying ACS event, defined by any of the following events within 24 hours prior to randomization:

• Hemodynamic instability: hypotension, defined as sustained systolic blood pressure of <90 mmHg due to cardiac failure with associated symptoms requiring inotropes
• Arrhythmic events: Ventricular storm (e.g., torsade, ventricular tachycardia, ventricular flutter)
• Cardiogenic shock or mechanical complication of myocardial infarction
• New York Heart Association (NYHA) class IV heart failure
• Left ventricular ejection fraction <20% at randomization (after all treatment procedures, based on the latest assessment of the LVEF using invasive or non-invasive assessment modalities)
• Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization despite antihypertensive therapy.
• Participant who has undergone or is scheduled to undergo CABG for treatment of the qualifying ACS event.
• Active liver disease defined as: (i) any known current infectious, neoplastic, or metabolic pathology of the liver or (ii) alanine aminotransferase (ALT) elevation >3x ULN or aspartate aminotransferase (AST) elevation >3x ULN, or total bilirubin elevation >2x ULN (except participant with Gilbert's syndrome) at the Screening visit, in the context of an ACS, and assessed as related to the index event and/or treatment procedures (such as PCI). Eligibility will be based on Investigator's judgement for participant who will be randomized.
• Renal insufficiency (eGFR <30 mL/min/1.73m2) at the Screening visit.
• Fasting triglycerides value >400 mg/dL (4.52 mmol/L; assessed by local labs) at randomization visit.
• Participant, who based on the Investigator's judgement, could reach the LDL-C target value of <55 mg/dL after 4 weeks on statin treatment only.
• Secondary hypercholesterolemia (based on medical history).
• Homozygous familial hypercholesterolemia (based on medical history).
• Participant on apheresis at the Screening visit.
• Ongoing or medical history of myopathy at the Screening visit.
• CK values ≥5x ULN at Screening visit and confirmed by repeat test during Screening (local lab) , in the context of an ACS, and assessed as related to the index event and/or treatment procedures (such as PCI) eligibility will be based on Investigator's judgement for participant who will be randomized (who will be switched to or initiated on the protocol-specified dose of high-intensity statin of atorvastatin ≥40 mg QD or rosuvastatin ≥20 mg QD). Unless a more stringent CK value threshold is mandated by a local regulatory authority (e.g., ≥3x ULN in Korea according to MFDS internal guideline).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

China · 15 centers

• Novartis Investigative Site — Beijing
• Novartis Investigative Site — Guangzhou
• Novartis Investigative Site — Luoyang
• Novartis Investigative Site — Xuzhou
• Novartis Investigative Site — Nanchang
• Novartis Investigative Site — Wenzhou
• Novartis Investigative Site — Beijing
• Novartis Investigative Site — Beijing
• … and 7 more centers

Spain · 9 centers

• Novartis Investigative Site — Santiago Compostela
• Novartis Investigative Site — Huelva
• Novartis Investigative Site — El Palmar
• Novartis Investigative Site — Las Palmas GC
• Novartis Investigative Site — Madrid
• Novartis Investigative Site — Madrid
• Novartis Investigative Site — Salamanca
• Novartis Investigative Site — Seville
• … and 1 more center

Germany · 6 centers

• Novartis Investigative Site — Leipzig
• Novartis Investigative Site — Coburg
• Novartis Investigative Site — Erfurt
• Novartis Investigative Site — Essen
• Novartis Investigative Site — Hennigsdorf
• Novartis Investigative Site — Kiel

France · 5 centers

• Novartis Investigative Site — Chambray-lès-Tours
• Novartis Investigative Site — Montpellier
• Novartis Investigative Site — Nantes
• Novartis Investigative Site — Pessac
• Novartis Investigative Site — Poitiers

Hungary · 5 centers

• Novartis Investigative Site — Pécs
• Novartis Investigative Site — Debrecen
• Novartis Investigative Site — Budapest
• Novartis Investigative Site — Budapest
• Novartis Investigative Site — Miskolc

Japan · 5 centers

• Novartis Investigative Site — Chikushino-shi
• Novartis Investigative Site — Kitakyushu
• Novartis Investigative Site — Kamakura
• Novartis Investigative Site — Sagamihara
• Novartis Investigative Site — Bunkyo Ku

India · 4 centers

• Novartis Investigative Site — Belagavi
• Novartis Investigative Site — Mumbai
• Novartis Investigative Site — Nashik
• Novartis Investigative Site — Bikaner

Poland · 4 centers

• Novartis Investigative Site — Gdansk
• Novartis Investigative Site — Katowice
• Novartis Investigative Site — Krakow
• Novartis Investigative Site — Opole

Switzerland · 3 centers

• Novartis Investigative Site — Bern
• Novartis Investigative Site — Geneva
• Novartis Investigative Site — Lucerne

Canada · 2 centers

• Novartis Investigative Site — Montreal
• Novartis Investigative Site — Québec

Hong Kong · 2 centers

• Novartis Investigative Site — Hong Kong
• Novartis Investigative Site — Hong Kong

South Korea · 2 centers

• Novartis Investigative Site — Seoul
• Novartis Investigative Site — Seoul

Australia · 1 center

• Novartis Investigative Site — Clayton

Identifiers

NCT: NCT07102628 · CKJX839A12309 · 2025-521670-34

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗